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tions, respectively. An intraocular pressure increase of >25 
mm Hg was recorded in 20% of patients, and 34% of pa-
tients began treatment with anti-glaucoma medication, but 
surgery was not needed for this condition.  Conclusions: DEX 
implant 0.7 mg was found to be well tolerated and effective 
with repeat treatments in clinical practice. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Macular oedema (ME) is a common sight-threatening 
complication seen in patients with branch retinal vein oc-
clusion (BRVO) and central retinal vein occlusion 
 Key Words 
 Dexamethasone intravitreal implant · Retinal vein 
occlusion · Macular oedema 
 Abstract 
 Purpose: To retrospectively evaluate the re-injection inter-
val, efficacy and safety of dexamethasone (DEX) intravitreal 
implant 0.7 mg in the treatment of macular oedema (ME) 
due to retinal vein occlusion (RVO) in Germany in 2009–2012. 
 Methods: Retrospective, multicentre, anonymised observa-
tional study of data collected from the first DEX implant 0.7 
mg injection through 3–6 months following the last injec-
tion. Data were included if the patient was >18 years old, had 
a diagnosis of ME secondary to branch or central RVO, and 
received at least 2 DEX implant 0.7 mg injections during rou-
tine practice.  Results: Data from 87 patients were analysed. 
Mean time to re-injection between first and second treat-
ments was 5.03 months in the total RVO population, and 5.46 
and 4.52 months for the branch and central RVO subpopula-
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(CRVO), which can be persistent and difficult to treat  [1] . 
In July 2010, dexamethasone (DEX) intravitreal implant 
0.7 mg (Ozurdex ® , Allergan Inc., Irvine, Calif., USA) was 
approved in the European Union for the first-line treat-
ment of ME secondary to BRVO or CRVO, although 
some patients in Germany have received DEX implant 0.7 
mg as part of an early access programme since October 
2009. DEX implant 0.7 mg represents a novel intravitreal 
drug delivery system consisting of a biodegradable copo-
lymer of lactic acid and glycolic acid, which contains mi-
cronised DEX. This corticosteroid has been shown to 
suppress inflammation  [2] , a key event in the pathophys-
iology of RVO and development of ME, by inhibiting ma-
jor inflammatory mediators that are associated with dis-
ease severity  [3] . DEX implant 0.7 mg delivers 0.7 mg to-
tal dose of DEX to the vitreous with gradual release over 
time allowing for sustained drug levels to the target areas 
while reducing the potential for side effects typically ob-
served from steroid administration.
 The DEX implant 0.7 mg has been shown to be effica-
cious in clinical trials in patients with inflammation of the 
posterior segment of the eye in non-infectious uveitis. Its 
efficacy in patients with ME following BRVO and CRVO 
has also been demonstrated in clinical trials like the Glob-
al Evaluation of Implantable Dexamethasone in Retinal 
Vein Occlusion with Macular Edema (GENEVA) trial 
and others  [4–6] , but less is known about the use and in-
jection burden of the DEX implant 0.7 mg in routine clin-
ical practice. This retrospective study was designed to re-
view the re-injection interval, efficacy and safety of DEX 
implant 0.7 mg in routine clinical practice in Germany in 
2009–2012, and therefore enhance knowledge of this 
treatment option.
 Methods 
 This was a retrospective, anonymised observational data col-
lection study conducted at 10 centres in Germany in 2009–2012 in 
patients with ME in RVO who were treated according to clinical 
need at the discretion of each investigator. The total number of 
patients identified at each separate centre was as follows: Bonn, 
n = 22; Bremen, n = 7; Karlsruhe, n = 13; Münster, n = 15; Munich/
München, n = 17; Dresden, n = 6; Heidelberg, n = 6; Ludwigshafen, 
n = 4; Marburg, n = 1, and München, n = 5. Of the 96 patients 
originally identified by the investigators, the case report forms of 
9 patients were excluded from the analysis from the Bonn centre 
(3/22 patients), the Münster centre (2/15 patients) and the first 
München centre (4/17 patients). These patients were excluded due 
to the following major protocol deviations: (a) the patient did not 
receive a DEX implant 0.7 mg at the baseline visit, or (b) the patient 
did not receive a minimum of 2 DEX implant 0.7 mg injections 
during the observation period. Data from 87 evaluable patients 
( ∼ 91% of the original patients selected) aged >18 years, who were 
diagnosed with ME secondary to BRVO or CRVO, who received 
at least 2 injections of DEX implant 0.7 mg in the study eye, and 
had follow-up data for 3–6 months following their latest DEX im-
plant 0.7 mg injection were therefore included in the analysis.
 As this was a retrospective study of routine clinical practice, 
there were no specified retreatment criteria, and this was per-
formed at the discretion of each investigator according to clinical 
need. This also meant that there was no significant delay between 
a diagnosis of recurrence of ME and the administration of the sec-
ond DEX implant 0.7 mg injection. Data from patients who re-
ceived DEX implant 0.7 mg as part of a clinical trial were excluded.
 The primary endpoint was the mean time between the first and 
second DEX implant 0.7 mg injection. Secondary endpoints in-
cluded best corrected visual acuity (BCVA) at 7–12 weeks after 
injection and central retinal thickness (CRT) measured by optical 
coherence tomography. Individual BCVA values were recorded in 
Snellen, but for the statistical analysis, the formula from Gregori et 
al.  [7] was used to convert Snellen to approximate early treatment 
diabetic retinopathy study (ETDRS) values. The time point of 7–12 
weeks was chosen for the secondary analysis based on the results 
of other clinical trials that suggested that after 7–12 weeks the 
chance of a relapse occurring is highest at this time point. In pa-
tients whose follow-up visits were not performed within 7–12 
weeks, the follow-up visit closest to this time window was chosen 
for analysis.
 Safety measures included adverse events monitoring, intraocu-
lar pressure (IOP), biomicroscopy and ophthalmoscopy. Data 
were collected and entered into a case report form, which was 
monitored centrally. Data were validated by a contract research 
organisation, MEDIDATA, and a statistical analysis plan was pro-
duced prior to database lock. Statistical analysis of the data was 
undertaken using statistical analysis software (SAS version 9.1) 
and MEDIDATA’s own software, and descriptive statistics were 
obtained. This included preparation of data listings and summary 
statistics (extreme values, interquartile section, mean and median 
values, standard deviation) or frequency distribution tables as ap-
propriate for each item. In this analysis, baseline was considered 
to be the patient’s first DEX implant 0.7 mg injection.
 Results 
 Baseline Characteristics and Demographics 
 Data from 87 (46 BRVO, 41 CRVO) patients were in-
cluded in this retrospective study ( table 1 ). At baseline, 
past and/or concomitant systemic conditions were report-
ed for 72.4% (63/87) of the patients overall. The most fre-
quent medical conditions were cardiovascular disorders, 
which were reported by 71.4% (45/63) of patients with 
medical conditions overall. The frequency of cardiovascu-
lar disorders was similar in the BRVO and CRVO sub-
groups [71.7% (33/46) and 73.1% (30/41)], respectively. 
Other medical conditions were reported less frequently.
 Patient ocular comorbidities are shown in  table 1 . A 




















   
   
   
   
   
   
   
   
   
   
   


























tients (7 patients each in the BRVO and CRVO sub-
groups) and prior to the start of treatment with DEX im-
plant 0.7 mg, 14.9% (13/87) of all patients suffered from 
glaucoma and 1 patient from ocular hypertension. Thir-
ty-four out of the 87 patients had a pseudophakic eye. 
Concerning past ocular surgeries and treatments, cata-
ract surgery was recorded in 39.0% (34/87) of patients, 
focal retinal laser treatment in 17.2% (15/87) of patients, 
panretinal photocoagulation in 14.9% (13/87) of patients, 
anti-glaucoma medication to treat elevated IOP in 13.8% 
(12/87) of patients (2 patients with glaucoma/ocular hy-
pertension did not receive treatment for this condition), 
pars plana vitrectomy in 9.2% (8/87) of patients, laser pe-
ripheral iridotomy in 1 patient, with other ocular treat-
ment recorded in 16.1% (14/87) of patients overall. The 
frequency of these events was similar in the BRVO and 
CRVO subgroups apart from laser peripheral iridotomy, 
which was only reported for a single patient in the BRVO 
subgroup.
 As shown in  table 1 , overall, 67% were men and the 
mean age was 68 years (range 47–86 years). Mean base-
line visual acuity was lower, and mean CRT was greater 
 Table 1.  Patient demographics and disease characteristics at baseline
Characteristics RVO (n = 87) BRVO (n = 46) CRVO (n = 41)
Mean age, years (range) 68 (47 – 86) 70 (50 – 85) 66 (47 – 86)
Sex, n (%)
Male 58 (67) 30 (65) 28 (68)
Female 29 (33) 16 (35) 13 (32)
Mean BCVA prior to first DEX implant 0.7 mg injection, 
approximate ETDRS letters 51 59 43
Mean CRT prior to first DEX implant 0.7 mg injection, μm (SD) 594.76 (217.87) 542.45 (198.54) 653.24 (26.41)
Median time from onset of symptoms to first treatment, days (%) 99a 81b 134c
<90 days 29 (33) 14 (30) 15 (37)
90 – 180 days 6 (7) 3 (7) 3 (7)
181 – 360 days 5 (6) 3 (7) 2 (5)
>360 days 18 (21) 7 (15) 11 (27)
Previous RVO treatment, n (%) 46 (53) 24 (52) 22 (54)
Bevacizumab 39 (85) 18 (75) 21 (96)
Triamcinolone 16 (35) 6 (25) 10 (46)
Ranibizumab 2 (4) 2 (8) NA
Other 7 (15) 4 (17) 3 (14)
Lens status of study eye prior to first DEX implant 0.7 mg injection
Phakic 50 (57.5) 25 (54.3) 25 (61.0)
Pseudophakic 32 (36.8) 17 (37.0) 15 (36.6)
Missing data 5 (5.7) 4 (8.7) 1 (2.4)
Opacity status of study eye prior to first DEX implant 0.7 mg injection
Opacity 41 (47.1) 20 (43.5) 21 (51.2)
No opacity 6 (6.9) 4 (8.7) 2 (4.9)
Missing data 40 (46.0) 22 (47.8) 18 (43.9)
Ischaemia in the study eye prior to first DEX implant 0.7 mg injection, 
n (%) 19 (22) 10 (22) 9 (22)
Ocular comorbidities in the study eye prior to first DEX implant
0.7 mg injection, n (%)
Glaucoma 13 (14.9) 6 (13) 7 (17.1)
Ocular hypertension 1 (1.1) 1 (2.2) 0
Patients with IOP-lowering medications prior to first DEX implant 
0.7 mg injection, n (%) 12 (14) 6 (13) 6 (15)
 ETDRS value is approximate and calculated based on a formula [7], with n = 78 for RVO overall, n = 39 for BRVO and n = 43 for 
CRVO. The mean time from the first injection to the last follow-up visit (when the patient may or may not have been retreated) was 
273.25 ± 96.06 days (range 98.0 – 548.0 days) for the RVO population (n = 84), 297.43 ± 95.99 days (range 117.0 – 548.0 days) for the 
BRVO subgroup (n = 46) and 243.97 ± 88.80 days (range 98.0 – 467.0 days) for the CRVO subgroup (n = 38). 
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for the CRVO population at baseline than for the BRVO 
population. Over half of the patients in this study (53%) 
had previously received treatment for RVO prior to re-
ceiving DEX implant 0.7 mg therapy, and the majority of 
these (85%) had received anti-vascular endothelial growth 
factor therapy.
 The mean time from the first injection to the last fol-
low-up visit (when the patient may or may not have been 
retreated) was 273.25 ± 96.06 days (range 98.0–548.0 
days) for the RVO population (n = 84), 297.43 ± 95.99 
days (range 117.0–548.0 days) for the BRVO subgroup 
(n = 46) and 243.97 ± 88.80 days (range 98.0–467.0 days) 
for the CRVO subgroup (n = 38).
 Efficacy Results 
 Data were analysed from 87 patients who received at 
least 2 injections of DEX implant 0.7 mg and had the re-
quired 3–6 months of follow-up data following their last 
DEX implant 0.7 mg injection. Of these 87 patients, 17 
patients (19.5%) received a third injection of DEX im-
plant 0.7 mg and 3 patients (3.4%) received a fourth injec-
tion. Sole treatment with DEX implant 0.7 mg was given 
to 39 out of 46 patients (84.8%) with BRVO and 39 out of 
41 patients (95.1%) with CRVO during the course of the 
observation period.
 Primary Efficacy Endpoint of Time to DEX Implant 
0.7 mg Re-Injection 
The mean time to DEX implant 0.7 mg re-injection 
between the first and second treatments was 141 days 
(5.03 months) for RVO overall, 153 days (5.46 months) 
for the BRVO subpopulation and 127 days (4.52 months) 
for the CRVO subpopulation, as shown in figure 1. Me-
dian re-injection intervals were 135 days [interquartile 
range (IQR) 99–169], 145 days (IQR 108–178) and 122 
days (IQR 84–147) for RVO overall, BRVO and CRVO, 
respectively.
 Secondary Efficacy Endpoints 
 Mean Change in BCVA from Baseline at 
Approximately 7–12 Weeks after the Last DEX 
Implant 0.7 mg Injection (ETDRS Equivalents) 
 As shown in  figure 2 , a mean approximate ETDRS let-
ter gain of 9 ± 20.42 letters was observed at a mean time 
of 77 ± 37.70 days (2.75 months) following the last DEX 
implant 0.7 mg injection in the RVO population. In the 
BRVO and CRVO subpopulations, mean gains observed 
were 6 ± 17.68 letters after 73 ± 29.57 days (2.61 months) 
and 12 ± 22.67 letters after 80 ± 45.40 days (2.86 months), 
respectively.
 Sub-Analysis Showing Mean Change in BCVA by 
Baseline Duration of ME at Approximately 7–12 
Weeks after the Last DEX Implant 0.7 mg Injection 
(ETDRS Equivalents) 
 As shown in  figure 3 , patients with ME of <90 days’ 
duration at baseline showed greater improvements in 
BCVA following treatment with DEX implant 0.7 mg 
compared with the population as a whole (e.g. patients 
with ME of any duration). In the RVO group of patients 
with ME of <90 days at baseline (n = 27), the mean change 
in BCVA from baseline was 15.63 ± 22.88 letters, with a 
mean time between the last injection and visit of 65.52 ± 
41.45 days. The corresponding changes in BCVA from 
baseline for the BRVO (n = 13) and CRVO (n = 14) sub-
populations were 9.62 ± 20.79 letters and 21.21 ± 24.05 
letters, respectively, and the mean time between the last 
injection and visit was 63.46 ± 29.84 days and 67.43 ± 
51.05 days, respectively.
 Sub-Analysis Showing Mean Change in BCVA 
by Baseline BCVA of <55 Letters and  ≥ 55 Letters 
at Approximately 7–12 Weeks after the Last DEX 
Implant 0.7 mg Injection (ETDRS Equivalents) 
 In a subgroup analysis of RVO patients with a BCVA 
of <55 letters (n = 36) at baseline, the mean BCVA prior 
to DEX implant 0.7 mg was 34.58 ± 12.03 letters (range 
20.0–50.0) and the BCVA approximately 7–12 weeks af-
ter the last DEX implant 0.7 mg injection was a mean of 
55.91 ± 14.77 letters (range 35.0–76.0). The change in 
BCVA for these patients with a baseline BCVA of <55 let-
ters was a mean of 20.91 ± 16.17 letters.






 Fig. 1. Mean time between the first and second injection of DEX 
implant 0.7 mg. 141 days is equivalent to 5.03 months, 153 days is 
equivalent to 5.46 months and 127 days is equivalent to 4.52 
months, if a month is assumed to be 28 days in length. Data avail-
able for 85/87 patients in the RVO group (46/46 patients in the 




















   
   
   
   
   
   
   
   
   
   
   


























 When RVO patients with a BCVA of  ≥ 55 letters were 
considered (n = 41), the mean BCVA prior to DEX im-
plant 0.7 mg was 64.51 ± 5.77 letters (range 55.0–76.0) 
and the BCVA approximately 7–12 weeks after the last 
DEX implant was 63.32 ± 17.74 letters (range 20.0–85.0). 
The change in BCVA for these patients with a baseline 
BCVA of  ≥ 55 letters was a mean of –1.20 ± 18.12 letters.
 Results for the BRVO and CRVO subgroups were sim-
ilar although the data must be interpreted with caution as 
only a small number of patients were included in each 
group.
 Patients Who Achieved a  ≥ 2- or 3-Line 
Improvement in BCVA 
 During the review period, 56.3% (49/87) of RVO pa-
tients achieved an improvement of  ≥ 2 lines compared 
with baseline, in a mean time of 65 days after the first in-
jection (n = 42; range 27–184 days) and 47 days after the 
second injection (n = 6; range 7–119 days). In the BRVO 
and CRVO subpopulations, 47.8% (22/46) of the BRVO 
patients and 65.8% (27/41) of the CRVO patients showed 
 ≥ 2 lines of BCVA improvement. In the BRVO group, the 
mean time to a  ≥ 2-line improvement was seen at 69 days 
after the first injection (n = 17; range 31–184 days) and at 
38 days after the second injection (n = 4; range 27–55 
days). In the CRVO group, the mean time to this im-
provement was at 62 days after the first injection (n = 25; 
range 27–118 days) and at 63 days after the second injec-
tion (n = 2; range 7–119 days). While it is expected that 
the time interval between injections would be approxi-
mately the same, the small difference seen could be ex-
plained by the small number of patients who required a 
second or third injection.
 In the RVO patients, 50.5% (44/87) showed an im-
provement of  ≥ 3 lines in comparison to baseline, and this 
was achieved 69 days after the first injection (n = 35; range 
27–208 days) and 50 days after the second injection (n = 
9; range 1–160 days). The sub-analyses for the BRVO and 
CRVO population showed that 41.3% (19/46) of all BRVO 
patients and 60.9% (25/41) of the CRVO patients achieved 
an improvement of  ≥ 3 lines compared with baseline. In 
the BRVO group, the mean time to this improvement of 
 ≥ 3 lines was achieved 79 days after the first injection (n = 
13; range 31–208 days) and 41 days after the second injec-
tion (n = 6; range 1–74 days). For the CRVO group, the 
time to this improvement was 63 days after the first injec-
tion (n = 22; range 27–118 days) and 67 days after the 
second injection (n = 3; range 7–160 days).
 Mean Change in Retinal Thickness 
 Reductions in CRT were seen at all time points during 
the study. For the 7- to 12-week post-injection time point, 
reductions in CRT compared with baseline were achieved 
after the first and second injection of as well as after the 
last injection of DEX implant 0.7 mg, as shown in  table 2 .
 Safety Findings 
 Adverse Events and Serious Adverse Events 
 Adverse events were recorded for 48.3% (42/87) of pa-
































 Fig. 2. Mean change in BCVA from baseline. ETDRS value is ap-
































 Fig. 3. Mean change in BCVA from baseline for the subgroup with 
ME of <90 days at baseline. ETDRS value is approximate and cal-
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ported in >1 patient. The most frequently recorded ad-
verse event was IOP increase, which occurred in 18.4% 
(16/87) of all RVO patients. Other adverse events report-
ed by more than 10% of patients included glaucoma 
(11.5%, 10/87) and eye laser surgery (10.3%, 9/87).
 During the review period, 6.9% of patients (6/87) re-
ported a serious adverse drug reaction; however, if cata-
ract progression or surgery are excluded, as these events 
were not related to the injection procedure itself, this 
drops to 2.3%.
 Table 2. CRT as assessed by optical coherence tomography during the observational period
RVO BRVO CRVO 
Mean CRT at baseline, μm 590.79 (43) 577.68 (25) 609.00 (18)
Change in CRT 7 – 12 weeks after first 
DEX implant 0.7 mg injection, μm –283.37 (43) –290.56 (25) –273.39 (18)
Mean CRT at baseline, μm 576.85 (40) 542.18 (28) 657.75 (12)
Change in CRT 7 – 12 weeks after second 
DEX implant 0.7 mg injection, μm –255.53 (40) –216.11 (28) –347.50 (12)
Mean CRT at baseline, μm 576.85 (34) 567.70 (23) 596.00 (11)
Change in CRT 7 – 12 weeks after last 
DEX implant 0.7 mg injection, μm –259.21 (34) –258.52 (23) –260.64 (11)
Figures in parentheses indicate numbers. Mean CRT: for patients with complete 7- to 12-week data after the first DEX implant 0.7 
mg injection. The mean time from the first injection to the last follow-up visit (when the patient may or may not have been retreated) 
was 273.25 ± 96.06 days (range 98.0 – 548.0 days) for the RVO population (n = 84), 297.43 ± 95.99 days (range 117.0 – 548.0 days) for the 
BRVO subgroup (n = 46) and 243.97 ± 88.80 days (range 98.0 – 467.0 days) for the CRVO subgroup (n = 38).







IOP increase 16 (18.4) 4 (8.7) 12 (29.3)
Glaucoma 10 (11.5) 9 (19.6) 1 (2.4)
Eye laser surgery 9 (10.3) 6 (13.0) 3 (7.3)
Cataract operation1 6 (6.9) 3 (6.5) 3 (7.3)
Retinal degeneration 6 (6.9) 2 (4.3) 4 (9.8)
Cataract 3 (3.4) 1 (2.2) 2 (4.9)
Conjunctival irritation 3 (3.4) 1 (2.2) 2 (4.9)
Retinal detachment 3 (3.4) 2 (4.3) 1 (2.4)
Conjunctival haemorrhage 2 (2.3) 1 (2.2) 1 (2.4)
Results are expressed as numbers with percentages in 
parentheses. The mean time from the first injection to the last 
follow-up visit (when the patient may or may not have been 
retreated) was 273.25 ± 96.06 days (range 98.0 – 548.0 days) for the 
RVO population (n = 84), 297.43 ± 95.99 days (range 117.0 – 548.0 
days) for the BRVO subgroup (n = 46) and 243.97 ± 88.80 days 
(range 98.0 – 467.0 days) for the CRVO subgroup (n = 38). 
1 One operation took place after the end of the formal data 
collection period.
 Table 4. Mean IOP recorded during the observational period for 
the RVO population (n = 87)
Mean IOP after first
DEX implant 0.7 mg
injection, mm Hg (n)
Mean IOP after second
DEX implant 0.7 mg
injection, mm Hg (n)
Time point
Baseline 15.3 (74)
0 – 6 weeks 16.9 (36) 15.4 (30)
7 – 12 weeks 16.1 (42) 16.3 (30)
13 – 17 weeks 15.4 (24) 18.3 (24)
18 – 22 weeks 16.0 (16) 15.8 (21)
23 – 26 weeks 15.3 (13) 14.6 (5)
>26 weeks 14.1 (12) 14.5 (2)
When the DEX implant 0.7 mg injections were performed 
during a visit, pre-injection pressures have been included for the 
mean calculation. The mean time from the first injection to the last 
follow-up visit (when the patient may or may not have been 
retreated) was 273.25 ± 96.06 days (range 98.0 – 548.0 days) for the 
RVO population (n = 84), 297.43 ± 95.99 days (range 117.0 – 548.0 
days) for the BRVO subgroup (n = 46) and 243.97 ± 88.80 days 




















   
   
   
   
   
   
   
   
   
   
   


























 Out of the 6 events reported, the following were as-
sessed by the investigator as having a casual or possible 
causal relationship with DEX implant 0.7 mg: 1 case of 
bulbar hypotension with choroidal detachment, which 
later resolved, 1 case of increased lens opacity and 2 cases 
of cataract surgery. One further cataract surgery and 1 
hospitalisation due to suspected glaucoma were reported 
as serious adverse events, but due to the retrospective na-
ture of this study, it was not possible for the investigator 
to assign a causal relationship.
 Special Interest Adverse Events – IOP, Glaucoma and 
Cataract Surgery 
 Table 4 shows the mean IOPs that were recorded at 
each time point. Anti-glaucoma medication, prescribed 
at the investigators’ discretion, was taken by 43.7% of all 
patients (38/87) during the observation period with 34.5% 
of all patients (30/87) initiating anti-glaucoma medica-
tion while receiving treatment with DEX implant 0.7 mg. 
No surgery for glaucoma was reported. An IOP >25 mm 
Hg was seen in 19.5% (17/87) of patients. Of these pa-
tients, 17.6% (3/17) were taking anti-glaucoma medica-
tion prior to the start of treatment with DEX implant 0.7 
mg, whereas 82.4% (14/17) of patients began anti-glauco-
ma medication during the observation period.
 Lens opacity was recorded in 47.1% (41/87) of patients 
at the baseline visit and 9.8% (4/41) of these patients had 
cataract surgery due to cataract progression during the 
mean observation period of up to 548 days (mean 273.25 
± 96.06 days). A fifth patient also had cataract surgery 
during the study, but data were not available on this pa-
tient’s lens opacity status at baseline.
 Discussion 
 Data from this retrospective, observational data col-
lection study in Germany show that with repeat usage of 
DEX implant 0.7 mg in clinical practice, the mean time 
interval between the first and second injection is 5.03 
months for patients with RVO (5.46 and 4.52 months in 
the BRVO and CRVO subpopulation, respectively). This 
time period of approximately 5 months is similar to data 
from the published GENEVA randomised controlled 
clinical trial  [4, 5] and comparable to data from more re-
cent real-life retrospective studies using the DEX implant 
0.7 mg for ME in RVO carried out in the UK, Italy, France 
and the USA  [8–12] ( table 5 ). In these retrospective real-
life studies, as well as a prospective study from Switzer-
land and a European multicentre study, re-injection in-
tervals in both treatment naïve and previously treated pa-
tients were typically between 5 and 7 months, with a trend 
towards a longer injection interval for subsequent injec-
tions  [8–14] . Many patient-specific factors are likely to 
impact on the need for retreatment and therefore treat-
ment should be individualised for each patient with the 
retreatment decision based on clinical judgement. Regu-
lar monitoring of the patient is therefore recommended 
especially as for some patients the optimum retreatment 
interval for the DEX implant 0.7 mg may be <5 months. 
This approach is aligned with that suggested by Coscas et 
al.  [14] , who recently published a retreatment algorithm 
for the retreatment with DEX implant 0.7 mg for ME sec-
ondary to RVO and recommend monthly examinations 
from 3 to 6 months following injection.
 As also shown by the data obtained, repeat DEX im-
plant 0.7 mg treatment results in lasting improvements in 
visual acuity and corresponding reductions in CRT in 













This study 87 5.03 56.3 50.5
Papathomas et al. [8], 2013 76 4.2 NR NR
Querques et al. [9], 2013 33 4.7 NR 30.3
Pommier and Meyer [10], 2012 220 5.35 61.5 50.8
Capone et al. [12], 2014 289 5.6 49.8 35.0
Ferrini and Ambresin [13], 2013 15 4.6 55.0 33.0
Coscas et al. [14], 2013 128 5.9 NR 39.0
NR = Not reported.
 Table 5. Comparison of efficacy data from 
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ments were more marked in the CRVO population than 
in the BRVO population. However, mean baseline visual 
acuity in the BRVO population was higher than in the 
CRVO population (59 vs. 43 approximate ETDRS let-
ters). As previously reported in randomised clinical trials, 
patients with a lower visual acuity at baseline had greater 
improvements following treatment presumably due to a 
ceiling effect  [4, 15] and therefore this finding is not sur-
prising.
 Data from the subgroup analysis of patients with ME 
of shorter duration (<90 days) and lower BCVA (<55 let-
ters) at baseline conducted in this study indicated that 
these patients had greater improvements in BCVA fol-
lowing treatment compared with the population as a 
whole. This finding is consistent with the results of the 
GENEVA trials, Ranibizumab for Macular Edema fol-
lowing Branch Retinal Vein Occlusion (BRAVO) studies, 
and the Standard Care versus Corticosteroid for RVO 
(SCORE) study  [4, 5, 16, 17] . Therefore, data obtained in 
this observational study of German clinical practice sup-
ports the growing evidence base that early treatment is 
beneficial.
 Expected side effects of intraocular steroid treatment 
include cataract formation and IOP increases as observed 
in previous studies with triamcinolone and fluocinolone 
acetonide  [18–21] . Over the course of this study, a low 
rate of cataract was reported with only 5 cataract opera-
tions performed, 4 of which were in patients who had lens 
opacity recorded at baseline. The majority of patients did 
not experience substantial IOP rises and the mean IOP at 
the expected peak effect for the DEX implant 0.7 mg (e.g. 
7–12 weeks after injection) was 16.1 mm Hg after the first 
injection. The mean IOP after the second DEX implant 
0.7 mg injection was 16.3 mm Hg, thereby indicating that 
IOP rises were similar for repeat treatment. While 34.5% 
of patients began anti-glaucoma medications at the inves-
tigators’ discretion during the observation period, no sur-
gery for this condition was reported. As IOP increases are 
known to occur with intravitreal steroids, regular moni-
toring and appropriate pharmacotherapy is recommend-
ed to control IOP  [19, 20, 22] . As alternative treatments 
to intravitreal steroid implant in patients with RVO may 
be associated with an increased injection frequency or 
side effects that are less easily managed, the advantages of 
treatment with the DEX implant 0.7 mg may outweigh 
the disadvantages of steroid-related side effects such as 
cataract and moderate IOP increase  [23, 24] .
 Limitations of this study include the small number of 
centres and hence, patients who had data analysed (10 
centres; n = 87), and its retrospective and observational 
nature. It is likely, however, that data obtained were re-
flective of clinical practice in Germany between 2009 and 
2012. Larger prospective observational studies are cur-
rently underway to more fully elucidate the usage pat-
terns of the DEX implant 0.7 mg in clinical practice, and 
they will allow comparisons with the results of the study 
reported herein.
 In conclusion, the findings of this retrospective study 
on the efficacy and safety of DEX implant 0.7 mg in rou-
tine clinical practice in Germany in 2009–2012 are in line 
with those reported in similar length or long-term studies 
in other European and US clinical practices  [8–14, 25] . A 
summary of the main findings from this study in com-
parison with other real-life studies is provided in  table 5 . 
As confirmed in this retrospective study, treatment with 
DEX implant 0.7 mg had a positive effect on the final vi-
sual function and had a favourable long-term safety pro-
file in patients with RVO. In particular, while IOP chang-
es were seen in some patients, these could be easily con-
trolled with medications, did not generally prevent 
retreatment, and surgery was not performed for IOP in-
crease and/or glaucoma. This study demonstrated that the 
main benefit of treatment with the DEX implant 0.7 mg 
over other treatment modalities is its acceptable risk-ben-
efit ratio and the long interval between injections. There 
are also likely to be cost savings from the use of the DEX 
implant 0.7 mg as well as an improvement in patient com-
pliance, but further research is needed to establish this. In 
addition, data are awaited from the COMO study, which 
will allow the comparison of the relative safety and effi-
cacy of DEX implant 0.7 mg and ranibizumab 0.5 mg, an 
anti-vascular endothelial growth factor medication. These 
are two different pharmacologic approaches that have 
very different mechanisms of action, and the findings of 
the COMO study should improve our understanding of 
the relative role of managing multiple inflammatory me-
diators in RVO. Data will also be available on the potential 
benefits of the different treatment schedules and the bur-
den of the number of injections on patients and health 
care systems. Coupled with the findings of this retrospec-
tive, real-life study, data obtained should help determine 
future management choices in patients with RVO.
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